Assessment of patients requiring an ‘’as needed treatment’’ with alemtuzumab therapy for resumed Multiple Sclerosis (MS) disease activity following the second dose of alemtuzumab from a single MS Centre in the North East of England

By Dr Alyaa H.A. Eissa, Neurology registrar ST5, Newcastle upon Tyne Hospitals NHS Foundation Trust

Project poster

Project write up

More MS Academy Medication Projects

Immunoglobulins levels in ocrelizumab therapy- UHS data
By Virginia Raluca Vasilescu, Clinical fellow in multiple sclerosis, University Hospitals Sussex NHS Foundation Trust
Reducing time to Disease-Modifying-Therapy initiation via homecare
By Sukhi Chahal, Advanced clinical pharmacist - MS & neurosciences, Oxford University Hospitals NHS Foundation Trust
Encouraging excellence, developing leaders, inspiring change

MS Academy was established five years ago and in that time has accomplished a huge amount. The six different levels of specialist MS training are dedicated to case-based learning and practical application of cutting edge research. Home to national programme Raising the Bar and the fantastic workstream content it is producing, this is an exciting Academy to belong to.